Summary: The present study reports on the acute effects of MK-801 on the histopathological outcome and blood flow changes during focal cerebral ischemia and reperfu sion. In addition, acute changes in the EEG and blood pressure are also reported. In 16 halothane-anesthetized cats, the left middle cerebral artery (MCA) was occluded for 2 h followed by 4 h of reperfusion. Thirty minutes after the onset of ischemia, eight animals were treated with 1 mg/kg of MK-801, while eight animals received saline. Blood flow from the peripheral MCA territory was measured with H2 clearance. There was a comparable reduction in blood flow (down to 20% of control) in the ischemic gyri of the two groups followed by a partial re covery after recirculation. There was a similar decrease in the EEG amplitude over the ischemic central MCA territory in the treated and the untreated group. Treat ment with MK-801 induced a burst suppression in the EEG and a transient drop (11.4 ± 6.5 mm Hg) in the mean Within the cascade of pathophysiologic events that lead to neuronal damage during cerebral isch emia, glutamate excitotoxicity via N-methyl-o aspartate (N MDA) receptors is thought to be an important factor (Garcia, 1984; Rothman, 1984; Meyer et aI., 1987 
a rapid increase (7-160-fold) in extracellular gluta mate levels has been found using the microdialysis technique, followed by a gradual return to baseline levels within 30 min of reperfusion (Benveniste et aI., 1984; Hagberg et aI., 1985; Globus et aI., 1988) . Activation of NMDA receptors by glutamate also results in an increase in the neuronal calcium con centration (Rothman and Olney, 1987) . There is also evidence of increased intracellular calcium dur ing reperfusion, which possibly involves NM DA re ceptors (Andine et aI., 1988) . These mechanisms can contribute to calcium-induced early and de layed neuronal death (Collins et aI., 1989; Siesj6 and Bengtsson, 1989) . Since noncompetitive NMDA receptor antagonists such as MK-80 1 have the ability to block the NM DA receptor-associated ion channel, they have been considered potential therapeutic agents in the treatment of clinical stroke (Wong et aI., 1986; Kemp et aI., 1987) .
In the past few years, various global and focal ischemia models have been utilized to test the ef fects of MK-801 treatment. The outcome of these trials widely varies with different test conditions (for reviews, see Beaughard et aI., 1989; Fleischer et a1., 1989; Uematsu et aI., 1991) . Recently, the neuroprotective effects of MK-80 1 have been inves tigated in a series of acute studies from the Glasgow laboratory both in cats (Ozyurt et aI., 1988; Park et aI., 1988a) and in rats (Park et a1., 1988b) . The data from these studies demonstrate that MK-80 1 effec tively reduces the early ischemic damage in perma nent ischemia, and therefore represent an important step in the neuropharmacology of this agent. Acute permanent ischemia, however, is a rather simplified model of human stroke (Wiebers et a1., 1990) . In clinical practice, the effect of acute ischemia is complicated by the subsequent recirculation (Sundt et aI., 1969; Weinstein et aI., 1986) , and the status of the patient is determined by late histopathological and neurological outcome (days or weeks after the insult). The extension of the validity of these find ings to clinical stroke requires the answer to a num ber of questions. Is there a similar neuroprotective effect of MK-80 1 in models of ischemia that include reperfusion? Is the beneficial effect of the drug pre served in the chronic phase of stroke, days after the ischemic insult?
In our laboratory, two parallel series of experi ments have been conducted in order to address these questions. The present study reports on the acute effects of MK-801 on histopathological out come and blood flow changes following a temporary MeA occlusion, while the chronic effects of MK-801 treatment will be published elsewhere (for pre liminary report, see Dezsi et a1., 1990) .
MATERIALS AND METHODS

Surgery and experimental procedures
The studies were undertaken in male cats weighing 2.5-3. 5 kg anesthetized with halothane (4% for induction, 1. 5% during the surgical preparation, and 1 % mainte nance during the study). The body temperature was main tained at 37°C with a servocontrolled heat lamp. The tra chea and the femoral arteries and veins were cannulated and the animals were ventilated with a small animal res pirator (Harvard Apparatus, South Natick, MA, U.S.A.). The head of the animal was mounted in a stereotaxic holder and the skin and muscles were removed from both sides of the skull. A burr hole was drilled in the left tem poral bone above the middle suprasylvian gyrus, and the dura was excised. A combined electrode was placed on the surface of the cortex for repeated H2 clearance mea surements and the hole was sealed with wax. Electrocor tical activity was measured from each hemisphere using brass screws fixed into the parietal bone over the middle ectosylvian gyrus, and the EEG was recorded on a mul tichannel polygraph (Grass Instrument Company, Quincy, MA, U.S.A.) along with the arterial blood pres sure. Blood samples (0.5 m!) were obtained repeatedly throughout the study and analyzed for pH, pC02, and p02 with a blood gas analyzer (Radiometer, Coppen hagen, Denmark) and for blood glucose using a glucose analyzer (Beckman, Brea, CA, U.S.A.).
The left middle cerebral artery (MCA) was exposed via a modified transorbital approach (O'Brien and Waltz, 1973; Urbanics et aI., 1989) and occluded in close prox imity to its branching from the internal carotid artery with a miniature Mayfield clip. After 2 h of occlusion, the clip was removed and the blood flow through the MCA was reinstated. Reperfusion lasted for 4 h. In eight animals with MCA occlusion, MK-801 (1 mg/kg) dissolved in sa line was infused intravenously over 2 min starting 30 min after the occlusion, while eight animals received only the vehicle. Animals were assigned to treatment or the vehi cle in alternating sequence. MK-801 was kindly provided by Merck Sharp & Dohme Laboratories (West Point, PA, U.S.A.).
For an estimate on MK-801 pharmacokinetics, arterial blood samples (1 m!) were taken at 1 and 4 h following the infusion of the agent. After centrifugation, plasma sam ples were kept frozen ( -80°C) until determination of MK-801 content by radioimmunoassay (RIA).
Blood flow measurement
Cortical blood flow was measured by the H2 clearance technique. H2 gas was locally generated by the method of Stosseck et al. (1974) as modified by Koshu et al. (1982) . The probe consisting of combined measuring (platinum, <I> = 130 /-Lm) and generating (platinum, <I> = 300 /-Lm) elec trodes was placed on the brain surface. The electrode assembly was surrounded by a silver ribbon as the refer ence electrode and another silver electrode was placed into the masseter muscle to act as a ground. A current of 50 /-LA was applied for 2 s to generate H2 gas and the disappearance rate of the gas was measured by a polaro graphic circuit based on the principles originally de scribed by Aukland et al. (1964) . Cerebral blood flow was measured prior to the occlusion, and at 5, 30, and 110 min after occlusion, as well as 5, 60, 120, 180, and 240 min into reperfusion. A monoexponential regression of the clear ance data yielded the quantitative value of cerebral blood flow after correction for the clearance of the H2 due only to diffusion (Koshu et aI., 1982) . The diffusion clearance rate was determined by performing a "blood flow" mea surement immediately after the animal was killed.
Histopathological analysis
After 4 h of recirculation, the animals were killed with an intravenous administration of potassium chloride so lution, and the brain was perfused with a 4% buffered formalin solution. It was then removed from the skull and stored in 10% formalin until histological evaluation by light microscopy. A 2-3 mm thick block of the frontal pole of each brain was removed, the hindbrain was de tached, and the remaining brain was sectioned into 10 blocks, each 3 mm thick. The blocks were paraffin em bedded and two sections (7 /-Lm) were obtained from each block 1.5 mm apart and stained with hematoxylin-eosin. One section was from the anterior surface and the other from the central part of the block.
The volumetric assessment of early infraction was mea sured by a technique similar to that described by Osborne et ai. (1987) . Each slide was examined under a micro scope in a blind fashion with respect to treatment of the animal, and the area of early neuronal damage was out lined. Areas were considered damaged if they contained cells with shrunken cell bodies with triangular darkly stained cytoplasm and a loss of discrete Nissl substance. Affected neurons were often accompanied by edematous neuropil in severely ischemic foci. Histopathological evaluation was based on earlier techniques (Ginsberg et ai., 1976; Tanaka et ai., 1988) with the modification that only the area of infarct was determined. Special care was taken to avoid "dark cell" artifacts (Osborne et ai., 1987) . The slide image was digitized and analyzed with an image analyzer (Brain V2, Drexel University, Philadelphia, PA, U.S.A.) to determine the area of ischemic damage in ab solute measure (mm 2 ); it was also expressed as a percent age of the area of the hemisphere. Similarly, cortical dam age in the ischemic hemisphere was also computed. The volume of ischemic damage was determined by integra tion knowing the distance between each coronal level for both the total hemisphere and the hemispheric cortex, and is given in mm 3 •
Experimental design and data processing
Due to the inherent variability of infarction in the MCA occlusion model in the cat, a preselection of cases was utilized to make this model more suitable for anti ischemic drug evaluation. Although this can potentially be done on the basis of intracranial vascular anatomy ABP , 100 Chen et ai., 1991) , EEG amplitude depression has also been repeatedly proven to be a useful selection criteria (Dora et ai., 1986; Urbanics et ai., 1989; Szabo and Ur banics, 1991) . A measure of the severity of the insult was obtained from the amplitude ratio of the EEG ipsilateral (left side) and contralateral to the stroke (Dora et ai., 1986) . The data were normalized so that the amplitude ratio was 1 immediately prior to MCA occlusion and an average of the 5, 15, and 30 min postocclusion values was used to grade stroke severity. All mild stroke cases (EEG depression of <30% of control) were excluded from the study.
Analysis of variance (ANOV A) and Student's t tests were used for the statistical analysis. For multiple com parisons, the Scheffe method (F test) was applied. The data are presented as mean values ± SD. Figure 1 shows the acute effects of MK-80 1 on blood pressure and EEG in a typical experiment. The top and bottom curves show changes in the arterial blood pressure. Immediately after MK-80 1 injection, there was a rapid pressure decrease fol lowed by a slower recovery. The middle two trac ings are the ipsilateral (left) and the contralateral (right) EEG beginning at 30 min into ischemia. The lower amplitude of the left hemispheric EEG is due to the stroke. There was a burst suppression pattern in the EEG that started a few minutes following MK-80 1 treatment and was repeated periodically for up to a few hours after treatment.
RESULTS
MABP 1 100 mmHg �------------------------------
Acute blood pressure reduction
The blood pressure data for the control and treated animals are shown in Fig. 2 . Mean arterial blood pressure was stable throughout the 6 h study, except for the transient pressure decrease of 11.4 ± 6.4 mm Hg following MK-80 1 treatment (p < 0.05), which recovered within a 1-2 h period. There were, however, no significant differences in blood pres sure between the treated and control animals at any time during the study. Similarly, no differences throughout the study or between the two groups were found in either the blood gas parameters or plasma glucose (Table 1) .
Changes in the EEG amplitude
There was a significant but comparable drop in the EEG amplitude ratio from the central MCA ter ritory in both groups following occlusion of the MCA (Fig. 3) . In the treated group, the amplitude ratio fell to 29 ± 17% of the control ratio within 1-5 min following occlusion while in the untreated group the drop was to 33 ± 11%. The correlation of average EEG depression between the groups during the first 30 min of ischemia was excellent (y = 0.6 + 0.95x; r = 0.94; p < 0.001). Individual data fol lowed near-normal distribution in both groups. In   FIG. 2 . Mean arterial blood pressure (MABP) during 2 h of middle artery (MeA) occlusion and 4 h of reperfusion. The an imals treated with MK-801 (TRT) showed a sudden significant decrease in blood pressure (+p < 0.05; ++p < 0.01) com pared to the control level. A sudden de crease upon MK-801 administration was followed by a slower recovery, which was complete during the first hour of reperfu sion. Data shown as mean ± SEM. the control animals, the EEG remained depressed with an EEG amplitude ratio at 40% of control or below throughout the experiment, while in the ani mals that received MK-801, the EEG amplitude ra tio increased following treatment, and by the end of the occlusive period was 55% of control. By the end of recovery, this ratio had risen to 73%. This recov ery of EEG amplitude ratio was significant (p < 0.05, AN OV A) in comparison to the untreated an imals.
Blood flow changes
Cortical blood flow of the peripheral MCA terri tory determined from the hydrogen clearance elec trode during and following occlusion is shown in Fig. 4 . Blood flow prior to MCA occlusion was very similar in both groups, i.e., 70 ± 42 ml 100 g -1 min -1 in the untreated animals and 78 ± 41 ml 100 g-I min -I in the treated animals. Following occlu sion, blood flow was depressed in both groups and remained depressed throughout the occlusive pe riod. Following reperfusion, flow increased toward the control preocclusion level at a similar rate in both the treated and control animals. There were no significant differences in cortical blood flow be tween the treated and untreated groups at any time during the study although there was a tendency for lower blood flow in the treated group immediately after MK-80 1 treatment, followed by a faster recov ery upon reopening the MCA. The administration of MK-80 1 30 min after the MeA occlusion reduced the total hemispheric dam age by 29% (from 1,756 ± 559 to 1,240 ± 859 mm 3 ). In the untreated group, 29 ± 10% of the hemisphere showed ischemic cell damage, while 20 ± 2% of the hemisphere was damaged in the treated group. The difference of these values, representing the inte grated volume of damage in the two groups, did not reach the level of significance (p = 0.068, t test). When the middle parietal (A20-A10) and posterior parietal (A 10-A3) regions were analyzed sepa rately, the ischemic damage was significantly lower in the treated than the control group (p < 0.05, AN OV A). Similar neuroprotection was seen in the cerebral cortex, where the volume of damage decreased from 996 ± 36 1 mm 3 (36 ± 8%) to 696 ± '"' o L.. 527 mm 3 (24 ± 13%). The spatial distribution of the damage is shown in Fig. 5 , both in the total hemisphere and in the hemispheric cortex, where in each coronal plane the area of ischemic dam age in the treated animals was equal to or smaller than that in the controls. Pairwise comparison showed significant treatment differences in each middle and posterior plane from A15 to A7 (Scheffe F test). The distribution of the ischemic damage in a rep resentative untreated and treated animal is shown in Fig. 6 . Although each animal exhibited equivalent EEG depression (to 27%) prior to treatment, the animal treated with MK-80 1 had less extensive damage. As represented in this figure, all animals showed some damage to the distributors at the len ticulostriate arteries. Plasma concentrations of MK-80 1 in animals treated with MK-80 1 (including the animals from this study along with another group of cats admin istered MK-801 in an identical fashion) were 280 ± 142 ng/ml (n = 16) 1 h after ischemia, which de creased to 150 ± 78 ng/ml at 4 h. The MK-80 1 assay in plasma from animals not administered the drug was between 1 and 2 ng/mi.
DISCUSSION
The present study was conducted on two match ing groups of cats with acute strokes as revealed by the equal depression in both EEG and cortical blood flow. It demonstrates that significant neuro protection can be achieved by postocclusion MK-80 1 treatment in the acute reperfusion phase follow ing temporary MeA occlusion in the cat. This result extends the findings of Ozyurt et ai. (1988) and Park et ai. (1988a,b) , who observed a similar neuropro tective effect in focal cerebral ischemia produced by permanent MeA occlusion. The authors ob served that both pretreatment and treatment after MeA occlusion with a relatively high dose of MK-80 1 (5 mg/kg i. v.) significantly reduced the volume of ischemic damage 6 h into ischemia in the cat. Similar effects were seen in the rat 3 h after MeA occlusion, when a 10-fold lower dose of MK-80 1 (0.5 mg/kg i. v.) was administered. The beneficial Time (min) effect of MK-80 1 was demonstrated by a decrease in the volume of ischemic damage both in the hemi sphere and the cerebral cortex. Table 2 compares these volumes (expressed as percent of total region) reported in the different studies as a function of treatment.
The relative size and distribution of the ischemic damage was similar to that obtained by Park et ai. (1988b) in the rat, a study in which halothane was also used as the anesthetic. MK-80 1, given in a dose comparable to that used in the present study, pro duced a transient drop in blood pressure in both studies. In cats anesthetized with chloralose, MK-80 1 treatment elicited a transient pressure elevation (Ozyurt et aI., 1988; Park et aI., 1988a) . Since hy potension can potentially increase ischemic brain damage (Osborne et aI., 1987) , due to a reduction in collateral blood flow to the region (Sundt et aI., 1969; Meyer et aI., 1987) , the hypotension induced by the interaction of MK-80 1 and halothane could counteract the beneficial effect of the agent derived from its glutamate antagonism. In spite of this pos sibility, both in the rat study and the current study, a reduction in ischemic damage was observed. Ac cording to recent findings (Busto et aI., 1987; Ikonomidou et aI., 1989; Buchan and Pulsinelli, 1990) , hypothermia has the potential for protecting against ischemic injury. In our studies, although the brain temperature was not controlled, the animal's core temperature was kept constant. Since the cor tical blood flow decrement in both the treated and untreated groups was comparable, it is unlikely that the temperature differences are appreciable be tween the two groups, suggesting that induced hy pothermia does not play a significant role in the observed neuroprotection of MK-80 1. An important difference between previous inves tigations and our study is the reperfusion of the MeA territory following 2 h of occlusion. A model of reperfusion mimics spontaneous recanalization or surgical revascularization, which often occurs in human stroke (Garcia, 1984; Meyer et aI., 1987) . Focal ischemia is a complex situation, in which the presence of collateral circulation may either im prove or worsen the neurological outcome (Sundt et aI., 1969; Siesjo and Bengtsson, 1989) . Restoration of flow can further increase the variability in the experimental outcome reducing the infarct or facil itating edema formation and even leading to death of the animal (Sundt et aI., 1969; Meyer et aI., 1987 The initial EEG depression upon MeA occlusion was comparable in both groups. The treated group, however, exhibited a better recovery of electrocor tical activity by the end of the experiment. The mechanism of this improvement is not known. The burst suppression in the EEG induced by MK-80 1 treatment has previously been reported in the liter ature (Fleischer et aI., 1989; Uematsu et aI., 199 1) together with sedation and other behavioral effects (Beaughard et aI., 1989; Michenfelder et aI., 1989) .
The response of cortical blood flow to MeA oc clusion was similar in both the treated and the un treated groups. The onset of ischemia was followed by an abrupt flow decrease (to 20% of control) that partially recovered after reperfusion (to 70% of con trol). In the MK-80 1-treated group, slightly lower flows were observed immediately after treatment. This could be attributed, however, to the transient reduction in blood pressure produced by the drug. The lack of an effect of MK -80 1 on blood flow in the ischemic region is in agreement with the data in the literature. Within the ischemic territory, no differ- FIG. 6 . Schematic representa tion of the histopathological damage produced by 2 h of mid dle cerebral artery occlusion followed by 4 h of reperfusion at eight coronal levels in an un treated animal (A) and an ani mal treated with MK-801 (8).
The two animals had an equiva lent depression of EEG am plitude ratio prior to drug treatment. All animals showed structural damage in the distri butions of the lenticulostriate arteries similar to that shown in this figure. The area of damage is indicated in gray.
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ence in blood flow between the treated and un treated animals was found, while outside the isch emic region, MK-80 1 has been shown to reduce blood flow in anesthetized rats (Park et aI., 1989) . In nonischemic conscious rats, NM DA receptor blockade elicited bidirectional responses (McCul loch et al., 1989) .
In the present study, undertaken in anesthetized animals, blood flow was measured in the peripheral MCA territory (middle suprasylvian gyrus). This re gion is known to exhibit similar, although less se vere, changes in blood flow, metabolism, electrical activity, and histology during ischemia than does the central MCA territory (Ginsberg et aI., 1976;  Tanaka et aI., 1988), and represents the perifocal region rather than the ischemic core. Due to a re sidual flow, it is potentially subject to pharmacolog ical protection during ischemia. In our study, how ever, treatment was not accompanied by any appre ciable hemodynamic consequences. Although we did not make any direct blood flow measurements in the central MCA territory, the EEG changes in the middle ectosylvian gyrus allowed us to draw conclusions on the degree of ischemia in this region. Our pharmacokinetic data show that plasma con centrations of MK-80 1 exceed the therapeutically effective level (30 ng/ml) (Lanier et aI., 1990 ) even 4 h after ischemia. Thus, the potential for neuropro tection exists even in the core during reperfusion, although it is expected to be less effective.
It is important to consider whether acute neuro protection by MK-80 1 is clinically relevant, and is representative of the histopathological damage days or weeks later. Early ischemic damage cannot be considered as an end point of stroke development. Park et ai. (1988b) speculated that the reduction in the lesion in treated versus control animals in the early phase could be the result only of the slowing of infarct development by the agent. Their prelimi nary data, however, showed a similar neuroprotec tive effect of MK-80 1 72 h following permanent MCA occlusion in the rat, suggesting that this may not be the case. Preliminary results in a chronic model of temporary ischemia induced by MCA oc clusion in our laboratory (Dezsi et aI., 1990) indi cate that 1 week after the insult only 11 % of the hemisphere shows signs of overt infarction in both MK-801-treated and untreated cats (compared with 20-29% early ischemic damage in the present study at 6 h). Thus, both the treated and untreated ani mals exhibit some histopathological recovery. Res toration of blood flow similarly to a recanalization of acute MCA occlusion (Meyer et aI., 1987) could lead to a partial recovery of the cells that show early ischemic damage. Since the late histological out come in the treated and control animals is similar, the assumption that the early improvement by MK-80 1 is only temporary seems reasonable. In addi tion, a number of recent studies could not show any histological benefit of MK-80 1 treatment in the late recovery phase following global ischemia (see Beaughard et aI., 1989; Fleischer et aI., 1989) . We suggest, therefore, that early neuroprotective ef fects are useful selection criteria in the development of drugs for the amelioration of ischemic damage. The clinical efficacy of the drug, however, should be decided above all on the basis of its ability to reduce the size of overt infarct and/or to improve the neurological outcome.
